Last reviewed · How we verify
Ganovo+ritonavir+/-Interferon nebulization
Ganovo+ritonavir+/-Interferon nebulization is a Antiviral combination therapy Small molecule drug developed by The Ninth Hospital of Nanchang. It is currently FDA-approved for COVID-19 (based on institutional use at Ninth Hospital of Nanchang), Severe respiratory viral infections.
This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response.
This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response. Used for COVID-19 (based on institutional use at Ninth Hospital of Nanchang), Severe respiratory viral infections.
At a glance
| Generic name | Ganovo+ritonavir+/-Interferon nebulization |
|---|---|
| Sponsor | The Ninth Hospital of Nanchang |
| Drug class | Antiviral combination therapy |
| Target | Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Ganovo acts as a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, while ritonavir enhances bioavailability by inhibiting cytochrome P450 metabolism. Interferon nebulization provides direct pulmonary immune stimulation and antiviral activity at the site of infection, particularly relevant for respiratory viral infections.
Approved indications
- COVID-19 (based on institutional use at Ninth Hospital of Nanchang)
- Severe respiratory viral infections
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea)
- Hepatotoxicity
- Interferon-related flu-like symptoms
- Hyperuricemia
Key clinical trials
- Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ganovo+ritonavir+/-Interferon nebulization CI brief — competitive landscape report
- Ganovo+ritonavir+/-Interferon nebulization updates RSS · CI watch RSS
- The Ninth Hospital of Nanchang portfolio CI
Frequently asked questions about Ganovo+ritonavir+/-Interferon nebulization
What is Ganovo+ritonavir+/-Interferon nebulization?
How does Ganovo+ritonavir+/-Interferon nebulization work?
What is Ganovo+ritonavir+/-Interferon nebulization used for?
Who makes Ganovo+ritonavir+/-Interferon nebulization?
What drug class is Ganovo+ritonavir+/-Interferon nebulization in?
What development phase is Ganovo+ritonavir+/-Interferon nebulization in?
What are the side effects of Ganovo+ritonavir+/-Interferon nebulization?
What does Ganovo+ritonavir+/-Interferon nebulization target?
Related
- Drug class: All Antiviral combination therapy drugs
- Target: All drugs targeting Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors
- Manufacturer: The Ninth Hospital of Nanchang — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for COVID-19 (based on institutional use at Ninth Hospital of Nanchang)
- Indication: Drugs for Severe respiratory viral infections
- Compare: Ganovo+ritonavir+/-Interferon nebulization vs similar drugs
- Pricing: Ganovo+ritonavir+/-Interferon nebulization cost, discount & access